{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
l-glutamine
to a specific field?
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Cipemastat (Ro 32-3555, tentative trade name Trocade) is a dipeptide, potent, competitive inhibitor of matrix metalloproteinases (MMP) 1, 8 and 13, which was under development by Roche for the potential treatment of rheumatoid arthritis. Cipemastat is a selective inhibitor of metalloproteinases 1, 8 and 13 over the related human matrix metalloproteinases stromelysin 1, and gelatinases A and B. Cipemastat mediated MMP inhibition leads to block the final common event in the destructive cascade resulting in the breakdown of cartilage and bone. Trocade has also been shown to inhibit cartilage destruction in vivo and to prevent structural joint damage in animal models of rheumatoid and osteoarthritis. Cipemastat was in phase II clinical trials for the treatment of rheumatoid arthritis. However, Roche discontinued the development of cipemastat because of an unfavorable risk-benefit profile.
Status:
Investigational
Source:
JAN:L-ISOPRENALINE HYDROCHLORIDE [JAN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Levisoprenaline (l-isoproterenol) is beta1- and beta2-adrenoreceptor agonist. In Japan, continuous inhalation of levisoprenaline is a recommended treatment for pediatric patients with acute severe exacerbation. Compared with salbutamol, l-isoproterenol reduced modified pulmonary index score more rapidly. But in most countries do not recommend continuous inhalation of l-isoproterenol to treat pediatric patients with acute severe exacerbation of asthma due to worsening asthma control. Levisoprenaline was used to cause experimental chronic heart failure in rats.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Salnacedin (also known as G 201) was developed as a topical anti-inflammatory agent; Salnacedin participated in phase II clinical trials in the USA for the treatment of dermatitis, acne, and psoriasis. However, all these studies were discontinued.
Status:
Investigational
Source:
NCT00474916: Phase 2 Interventional Completed Neuropathic Pain
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
KRN-5500, a spicamycin derivative, is a nucleoside-like antibiotic with a broad spectrum of antitumor activity against human cancer cell lines. It also may have value in the treatment of neuropathic pain.
Status:
Investigational
Source:
J Nutr Sci Vitaminol (Tokyo). Aug 2008;54(4):315-20.: Not Applicable Human clinical trial Completed N/A
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Dehydroascorbic acid (DHA) is an oxidized form of ascorbic acid. Ascorbic acid is transported in its oxidized form via GLUT1 across the blood-brain barrier. Dehydroascorbic acid delay low-density lipoprotein (LDL) oxidation when added before the initiation of the process, they accelerate the process if added to minimally oxidized LDL. Dehydroascorbic acid is used as biochemical markers of oxidative stress in clinical investigations. Dehydroascorbic acid has been used as a vitamin C dietary supplement.
Status:
Investigational
Source:
NCT01449032: Phase 2 Interventional Completed Chronic Ischemic Heart Disease
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Methylselenocysteine is a part of the mammalian physiology and is a well-tolerated, versatile and economical antiangiogenic agent. This compound participated in clinical trial to determine if vitamin supplementation with this compound could restore disruption of circadian rhythm in shift workers. The preclinical efficacy of methylselenocysteine has shown the combination of methylselenocysteine with androgen deprivation therapy can be useful for the treatment of advanced prostate cancer.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Vinleucinol (also known as vinblastine-isoleucinate or V-LEU) was developed as a vinca alkaloid derivative. This compound exhibited superior antitumor activity in malignant melanoma, small cell lung carcinoma, and breast cancer lines. Experiments on animals have shown that metabolite of vinleucinol was mainly responsible for the antitumor.
Status:
Investigational
Source:
NCT00003914: Phase 2 Interventional Completed Kidney Cancer
(1999)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Dolastatin 10 is an unusual peptide of marine origin which binds to tubulin, inhibits microtubule assembly, resulting in the formation of tubulin aggregates and inhibition of mitosis. Dolastatin 10 has been used in trials phase II studying the treatment of Sarcoma, Leukemia, Lymphoma, Liver Cancer, among others. In case of hormone-refractory prostate cancer, it lacks significant clinical activity as a single agent and also dolastatin-10 is inactive against hepatobiliary and pancreatic carcinomas.
Status:
Investigational
Source:
NCT00003010: Phase 3 Interventional Completed Breast Cancer
(1997)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Marimastat is a broad spectrum matrix metalloprotease (MMP) inhibitor. It is an angiogenesis and metastasis inhibitor. It mimics the peptide structure of natural MMP substrates and binds to matrix metalloproteases, thereby preventing the degradation of the basement membrane by these proteases. This antiprotease action prevents the migration of endothelial cells needed to form new blood vessels. Inhibition of MMPs also prevents the entry and exit of tumor cells into existing blood cells, thereby preventing metastasis. Marimastat has been in pivotal phase III trials in glioblastoma, breast, ovarian and small and non-small cell lung cancer, but these trials have all been discontinued because marimastat failed to show superior efficacy over either standard chemotherapy or placebo.
Status:
Investigational
Source:
NCT00004033: Phase 2 Interventional Completed Malignant Mesothelioma
(1998)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
